Alterity Therapeutics publishes transcript of chairman's address to 2026 annual general meeting
ATHE•
ATHE•Alterity Therapeutics published its chairman’s 2026 annual general meeting address, which outlined FDA alignment on key Phase 3 design elements and a potential registration pathway for ATH434. The company reported A$41.3 million in cash at September-end and said it was evaluating funding options for the pivotal trial.
Chairman Julian Babarczy outlined FDA alignment on key trial design elements and a potential registration pathway for ATH434 in multiple system atrophy. The company said launching the pivotal trial requires substantial funding, and potential pharmaceutical partnerships and other strategic financing options remain under evaluation.
Alterity reported cash of A$41.3 million at September-end. Manufacturing reached the first ATH434 registration batch, and a new U.S. composition of matter patent extends protection to 2045.